News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,530 Results
Type
Article (41341)
Company Profile (265)
Press Release (688908)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204838)
Career Advice (2032)
Deals (35582)
Drug Delivery (128)
Drug Development (81511)
Employer Resources (173)
FDA (16507)
Job Trends (14981)
News (346811)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2594)
Accelerated approval (47)
Adcomms (26)
Allergies (171)
Alliances (49579)
ALS (210)
Alzheimer's disease (1792)
Antibody-drug conjugate (ADC) (442)
Approvals (16883)
Artificial intelligence (656)
Autoimmune disease (289)
Automation (56)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (220)
Biotechnology (175)
Bladder cancer (187)
Brain cancer (71)
Breast cancer (747)
Cancer (5782)
Cardiovascular disease (467)
Career advice (1724)
Career pathing (42)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (892)
Cervical cancer (47)
Clinical research (70776)
Collaboration (2043)
Company closure (5)
Compensation (1387)
Complete response letters (79)
COVID-19 (2741)
CRISPR (107)
C-suite (1112)
Cystic fibrosis (152)
Data (7827)
Decentralized trials (3)
Denatured (27)
Depression (160)
Dermatology (85)
Diabetes (586)
Diagnostics (6922)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (315)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (283)
Earnings (92023)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119447)
Executive appointments (1077)
FDA (20210)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1714)
Gene editing (233)
Generative AI (55)
Gene therapy (718)
GLP-1 (1052)
Government (4729)
Grass and pollen (6)
Guidances (408)
Healthcare (18992)
HIV (79)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (287)
Immuno-oncology (92)
Indications (191)
Infectious disease (3078)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (99)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (759)
Lymphoma (429)
Machine learning (60)
Management (59)
Manufacturing (1043)
MASH (185)
Medical device (13925)
Medtech (14045)
Mergers & acquisitions (20156)
Metabolic disorders (1493)
mRNA (204)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (412)
Neuropsychiatric disorders (105)
Neuroscience (3292)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (78)
Obesity (698)
Opinion (286)
Ovarian cancer (218)
Pain (252)
Pancreatic cancer (299)
Parkinson's disease (358)
Partnered (33)
Patents (592)
Patient recruitment (666)
Peanut (62)
People (59560)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22063)
Phase 2 (31181)
Phase 3 (23204)
Pipeline (8622)
Policy (314)
Postmarket research (2568)
Preclinical (9402)
Press Release (64)
Prostate cancer (298)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1069)
Real estate (5969)
Recruiting (70)
Regulatory (25372)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (288)
Series B (212)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3639)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (450)
Women's health (124)
Worklife (20)
Date
Today (208)
Last 7 days (927)
Last 30 days (3581)
Last 365 days (30256)
2026 (12281)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (348)
Arkansas (14)
Asia (39658)
Australia (6502)
California (13210)
Canada (3747)
China (1332)
Colorado (566)
Connecticut (573)
Delaware (403)
Europe (85817)
Florida (1977)
Georgia (424)
Hawaii (3)
Idaho (62)
Illinois (1048)
India (89)
Indiana (598)
Iowa (23)
Japan (533)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1582)
Massachusetts (9427)
Michigan (362)
Minnesota (714)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (142)
New Hampshire (84)
New Jersey (3477)
New Mexico (29)
New York (3453)
North Carolina (1677)
North Dakota (9)
Northern California (6624)
Ohio (396)
Oklahoma (23)
Oregon (41)
Pennsylvania (2657)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5205)
Tennessee (210)
Texas (2094)
United States (46599)
Utah (393)
Vermont (1)
Virginia (321)
Washington D.C. (80)
Washington State (1056)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
730,530 Results for "cutera inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cutera® Announces the Official Australia and New Zealand Launch of Secret™ by Cutera
August 15, 2025
·
9 min read
Deals
Cutera, Inc. Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Cutera, Inc. granted a total of 44,500 non-qualified inducement stock options to six employees.
May 30, 2024
·
1 min read
Business
Cutera Announces First Quarter 2024 Financial Results
Cutera, Inc., a leading provider of aesthetic and dermatology solutions, reported financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
17 min read
Biotech Bay
Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023
Cutera, Inc., a leading provider of aesthetic and dermatology solutions, announced certain preliminary, unaudited financial results for the year ended December 31, 2023.
January 9, 2024
·
4 min read
Business
Cutera, Inc. to Announce Third Quarter Results on November 8, 2023
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the third quarter of 2023 after the market close on Wednesday, November 8, 2023.
October 25, 2023
·
1 min read
Business
Cutera, Inc. Appoints Brent Hauser as President, International
Cutera, Inc. is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023.
October 2, 2023
·
3 min read
Biotech Bay
Cutera, Inc. Reports Inducement Grants as permitted by the Nasdaq Listing Rules - November 16, 2023
Cutera, Inc., a leading provider of aesthetic and dermatology solutions, announced that Stephana Patton, who joined Cutera on November 13, 2023, as the Chief Legal Officer will receive a grant of inducement awards.
November 16, 2023
·
1 min read
Business
Cutera to Announce First Quarter Results on May 9, 2024
Cutera, Inc. today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024.
April 26, 2024
·
1 min read
Biotech Beach
Cutera® Announces the North America Launch of xeo®+
Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, today announces the launch of xeo+, a pioneering laser and light-based multi-application platform built on a rich history of excellence in performance and innovation.
April 11, 2024
·
3 min read
Biotech Bay
Cutera, Inc. to Participate in Upcoming Investor Conferences - November 10, 2023
Cutera, Inc. announced that Taylor Harris, Chief Executive Office, and Greg Barker, Vice President of Corporate FP&A and Investor Relations, will participate in Fireside Chats at the following upcoming investor conferences
November 10, 2023
·
1 min read
1 of 73,053
Next
